<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293254</url>
  </required_header>
  <id_info>
    <org_study_id>0518-019</org_study_id>
    <secondary_id>2005_097</secondary_id>
    <nct_id>NCT00293254</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study will investigate the safety and efficacy of raltegravir as a therapy for Human
      Immunodeficiency Virus (HIV)-infected patients failing current therapy with 3-class antiviral
      resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary double-blind study of raltegravir versus placebo was extended to 156 weeks and
      was followed by an open-label raltegravir phase in which continuing participants from both
      the raltegravir and placebo groups received open-label raltegravir for an additional 84 weeks
      for a maximum duration of up to 240 weeks. Participants who had viral failure after Week 16
      may have received open-label raltegravir until Week 240.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL at Week 16</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants who achieved HIV RNA &lt;400 copies/mL at Week 16</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Percentage of participants who achieved HIV RNA &lt;400 copies/mL at Week 48</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL</measure>
    <time_frame>156 Weeks</time_frame>
    <description>Percentage of participants who achieved HIV RNA &lt;400 copies/mL at Week 156</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL</measure>
    <time_frame>240 Weeks</time_frame>
    <description>Percentage of participants who achieved HIV RNA &lt;400 Copies/mL at Week 240</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL at Week 16</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL</measure>
    <time_frame>156 Weeks</time_frame>
    <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 156</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL</measure>
    <time_frame>240 Weeks</time_frame>
    <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 240</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-Blind Extension - Week 156: Percentage of Participants Without Loss of Virologic Response</measure>
    <time_frame>156 Weeks</time_frame>
    <description>For participants with confirmed HIV RNA levels &lt;50 copies/mL on 2 consecutive visits, loss of virologic response is the occurrence of the first value &gt;50 copies/mL or loss to follow-up; participants who never achieved HIV RNA &lt;50 copies/mL on 2 consecutive visits are also considered as having loss of virologic response. Events are the numbers of participants with loss of virologic response versus the numbers of participants with no loss of virologic response (event-free).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HIV RNA (Log 10 Copies/mL) at Week 16</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>Mean change from baseline at Week 16 in HIV RNA (log 10 copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HIV RNA (log10 Copies/mL) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Mean change from baseline at Week 48 in HIV RNA (log10 copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-Blind Extension - Week 156: Change From Baseline in HIV RNA (log10 Copies/mL)</measure>
    <time_frame>Baseline and Week 156</time_frame>
    <description>Mean change from baseline at Week 156 in HIV RNA (log10 copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-Label Extension - Week 240: Change From Baseline in HIV RNA (log10 Copies/mL)</measure>
    <time_frame>Baseline and Week 240</time_frame>
    <description>Mean change from baseline at Week 240 in HIV RNA (log10 copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 16</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>Mean change from baseline at Week 16 in CD4 cell count (cells/mm^3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Mean change from baseline at Week 48 in CD4 cell count (cells/mm^3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-Blind Extension - Week 156: Change From Baseline in CD4 Cell Count(Cells/mm^3)</measure>
    <time_frame>Baseline and Week 156</time_frame>
    <description>Mean change from baseline at Week 156 in CD4 cell count (cells/mm^3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-Label Extension - Week 240: Change From Baseline in CD4 Cell Count (Cells/mm^3)</measure>
    <time_frame>Baseline and Week 240</time_frame>
    <description>Mean change from baseline at Week 240 in CD4 cell count (cells/mm^3)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">351</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>raltegravir potassium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir potassium</intervention_name>
    <description>Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ISENTRESSâ„¢</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo</intervention_name>
    <description>Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be HIV positive with HIV RNA values that are within ranges required by
             the study

          -  Patient must have documented failure of certain antiretroviral therapy

          -  Patient must be on the same antiretroviral therapy for at least the past two months

        Exclusion Criteria:

          -  Patient less than 16 years old

          -  Additional study criteria will be discussed and identified by the study doctor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975.</citation>
    <PMID>18650512</PMID>
  </reference>
  <reference>
    <citation>Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.</citation>
    <PMID>18650513</PMID>
  </reference>
  <results_reference>
    <citation>Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.</citation>
    <PMID>20085491</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2006</study_first_submitted>
  <study_first_submitted_qc>February 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <results_first_submitted>August 20, 2009</results_first_submitted>
  <results_first_submitted_qc>September 29, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2009</results_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase 3; First Patient In: 08-Mar-2006; Last Patient Last Visit (LPLV) for Week 48: 31-Jul-2007; Extension Study LPLV Week 240: May 2011
53 sites (US, Brazil, Canada, Colombia, Mexico, and Puerto Rico).</recruitment_details>
      <pre_assignment_details>Patients failed prior antiretroviral therapy (HIV RNA &gt;1000 copies/mL), and had documented resistance to at least one drug in each class of licensed oral antiretroviral therapy (Nucleoside Reverse Transcriptase inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors). All patients must have met laboratory criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir 400 mg b.i.d. + OBT</title>
        </group>
        <group group_id="P2">
          <title>Placebo + OBT</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Study - Double-Blind Week 0-48</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Continuing in Double-Blind</title>
              <participants_list>
                <participants group_id="P1" count="177">Excludes participants who entered the Open-Label Post-Virologic Failure (OLPVF) Phase</participants>
                <participants group_id="P2" count="55">Excludes participants who entered the OLPVF phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved or trial terminated at site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entered OLPVF Phase</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension - Double-Blind Week 49-156</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="54">1 of 55 participants who completed Week 48 did not enter the extension study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved/Site Stopped Trial</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entered OLPVF Phase</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension - Open-Label Week 157-240</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="19">6 of 25 participants who completed the double-blind phase did not enter this open-label phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Post Virologic Failure Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50">Number of participants who failed treatment and consented to enter the OLPVF phase</participants>
                <participants group_id="P2" count="64">Number of participants who failed treatment and consented to enter the OLPVF phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved/Site Stopped Trial</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir 400 mg b.i.d. + OBT</title>
        </group>
        <group group_id="B2">
          <title>Placebo + OBT</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="230"/>
            <count group_id="B2" value="119"/>
            <count group_id="B3" value="349"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" lower_limit="16" upper_limit="67"/>
                    <measurement group_id="B2" value="46.5" lower_limit="17" upper_limit="70"/>
                    <measurement group_id="B3" value="45.7" lower_limit="16" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cluster of Differentiation 4 (CD4) Cell Count</title>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146" lower_limit="1" upper_limit="757"/>
                    <measurement group_id="B2" value="163" lower_limit="0" upper_limit="674"/>
                    <measurement group_id="B3" value="152" lower_limit="0" upper_limit="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA)</title>
          <units>copies/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49159" lower_limit="200" upper_limit="750000"/>
                    <measurement group_id="B2" value="47850" lower_limit="200" upper_limit="750000"/>
                    <measurement group_id="B3" value="48709" lower_limit="200" upper_limit="750000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL at Week 16</title>
        <description>Percentage of participants who achieved HIV RNA &lt;400 copies/mL at Week 16</description>
        <time_frame>16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL at Week 16</title>
          <description>Percentage of participants who achieved HIV RNA &lt;400 copies/mL at Week 16</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="71.3" upper_limit="82.6"/>
                    <measurement group_id="O2" value="42.9" lower_limit="33.8" upper_limit="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL at Week 48</title>
        <description>Percentage of participants who achieved HIV RNA &lt;400 copies/mL at Week 48</description>
        <time_frame>48 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL at Week 48</title>
          <description>Percentage of participants who achieved HIV RNA &lt;400 copies/mL at Week 48</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" lower_limit="64.7" upper_limit="76.8"/>
                    <measurement group_id="O2" value="37.8" lower_limit="29.1" upper_limit="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL</title>
        <description>Percentage of participants who achieved HIV RNA &lt;400 copies/mL at Week 156</description>
        <time_frame>156 Weeks</time_frame>
        <population>The analysis population was based on a non-completer equals failure approach where missing values for participants who discontinued the study for any reason were considered treatment failures.
Participants who experienced virologic failure after Week 16 are counted also as treatment failures for the subsequent virologic efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL</title>
          <description>Percentage of participants who achieved HIV RNA &lt;400 copies/mL at Week 156</description>
          <population>The analysis population was based on a non-completer equals failure approach where missing values for participants who discontinued the study for any reason were considered treatment failures.
Participants who experienced virologic failure after Week 16 are counted also as treatment failures for the subsequent virologic efficacy analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" lower_limit="43.6" upper_limit="56.9"/>
                    <measurement group_id="O2" value="21.0" lower_limit="14.1" upper_limit="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL</title>
        <description>Percentage of participants who achieved HIV RNA &lt;400 Copies/mL at Week 240</description>
        <time_frame>240 Weeks</time_frame>
        <population>The analysis population was based on a non-completer equals failure approach where missing values for participants who discontinued the study for any reason were considered treatment failures.
Participants who experienced virologic failure after Week 16 are counted also as treatment failures for the subsequent virologic efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
            <description>Raltegravir 400 mg b.i.d. plus OBT includes all participants initially randomized to raltegravir. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants continued to receive raltegravir plus OBT until Week 240.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
            <description>Placebo plus OBT includes all participants initially randomized to placebo. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants received raltegravir plus OBT until Week 240.</description>
          </group>
        </group_list>
        <measure>
          <title>Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA &lt;400 Copies/mL</title>
          <description>Percentage of participants who achieved HIV RNA &lt;400 Copies/mL at Week 240</description>
          <population>The analysis population was based on a non-completer equals failure approach where missing values for participants who discontinued the study for any reason were considered treatment failures.
Participants who experienced virologic failure after Week 16 are counted also as treatment failures for the subsequent virologic efficacy analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" lower_limit="39.1" upper_limit="52.3"/>
                    <measurement group_id="O2" value="13.4" lower_limit="7.9" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL at Week 16</title>
        <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 16</description>
        <time_frame>16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL at Week 16</title>
          <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 16</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" lower_limit="55.4" upper_limit="68.3"/>
                    <measurement group_id="O2" value="36.1" lower_limit="27.5" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL at Week 48</title>
        <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 48</description>
        <time_frame>48 Weeks</time_frame>
        <population>Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL at Week 48</title>
          <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 48</description>
          <population>Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" lower_limit="53.0" upper_limit="66.1"/>
                    <measurement group_id="O2" value="34.5" lower_limit="26.0" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL</title>
        <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 156</description>
        <time_frame>156 Weeks</time_frame>
        <population>Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL</title>
          <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 156</description>
          <population>Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="41.0" upper_limit="54.3"/>
                    <measurement group_id="O2" value="17.6" lower_limit="11.3" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL</title>
        <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 240</description>
        <time_frame>240 Weeks</time_frame>
        <population>Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
            <description>Raltegravir 400 mg b.i.d. plus OBT includes all participants initially randomized to raltegravir. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants continued to receive raltegravir plus OBT until Week 240.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
            <description>Placebo plus OBT includes all participants initially randomized to placebo. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants received raltegravir plus OBT until Week 240.</description>
          </group>
        </group_list>
        <measure>
          <title>Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA &lt;50 Copies/mL</title>
          <description>Percentage of participants who achieved HIV RNA &lt;50 copies/mL at Week 240</description>
          <population>Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" lower_limit="34.9" upper_limit="48.0"/>
                    <measurement group_id="O2" value="13.4" lower_limit="7.9" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Double-Blind Extension - Week 156: Percentage of Participants Without Loss of Virologic Response</title>
        <description>For participants with confirmed HIV RNA levels &lt;50 copies/mL on 2 consecutive visits, loss of virologic response is the occurrence of the first value &gt;50 copies/mL or loss to follow-up; participants who never achieved HIV RNA &lt;50 copies/mL on 2 consecutive visits are also considered as having loss of virologic response. Events are the numbers of participants with loss of virologic response versus the numbers of participants with no loss of virologic response (event-free).</description>
        <time_frame>156 Weeks</time_frame>
        <population>Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Double-Blind Extension - Week 156: Percentage of Participants Without Loss of Virologic Response</title>
          <description>For participants with confirmed HIV RNA levels &lt;50 copies/mL on 2 consecutive visits, loss of virologic response is the occurrence of the first value &gt;50 copies/mL or loss to follow-up; participants who never achieved HIV RNA &lt;50 copies/mL on 2 consecutive visits are also considered as having loss of virologic response. Events are the numbers of participants with loss of virologic response versus the numbers of participants with no loss of virologic response (event-free).</description>
          <population>Participants who experienced virologic failure after Week 16 are also counted as treatment failures for the subsequent virologic efficacy analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3"/>
                    <measurement group_id="O2" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HIV RNA (Log 10 Copies/mL) at Week 16</title>
        <description>Mean change from baseline at Week 16 in HIV RNA (log 10 copies/mL)</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace &lt;400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: Baseline carry-forward for all failures/discontinued due to lack of efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV RNA (Log 10 Copies/mL) at Week 16</title>
          <description>Mean change from baseline at Week 16 in HIV RNA (log 10 copies/mL)</description>
          <population>Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace &lt;400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: Baseline carry-forward for all failures/discontinued due to lack of efficacy</population>
          <units>HIV RNA (log10 copies/mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" lower_limit="-2.05" upper_limit="-1.78"/>
                    <measurement group_id="O2" value="-1.06" lower_limit="-1.26" upper_limit="-0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HIV RNA (log10 Copies/mL) at Week 48</title>
        <description>Mean change from baseline at Week 48 in HIV RNA (log10 copies/mL)</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace &lt;400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: Baseline carry-forward for all failures/discontinued due to lack of efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV RNA (log10 Copies/mL) at Week 48</title>
          <description>Mean change from baseline at Week 48 in HIV RNA (log10 copies/mL)</description>
          <population>Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace &lt;400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: Baseline carry-forward for all failures/discontinued due to lack of efficacy</population>
          <units>HIV RNA (log10 copies/mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" lower_limit="-1.90" upper_limit="-1.59"/>
                    <measurement group_id="O2" value="-0.87" lower_limit="-1.08" upper_limit="-0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Double-Blind Extension - Week 156: Change From Baseline in HIV RNA (log10 Copies/mL)</title>
        <description>Mean change from baseline at Week 156 in HIV RNA (log10 copies/mL)</description>
        <time_frame>Baseline and Week 156</time_frame>
        <population>Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace &lt;400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: Baseline carry-forward for all failures/discontinued due to lack of efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Double-Blind Extension - Week 156: Change From Baseline in HIV RNA (log10 Copies/mL)</title>
          <description>Mean change from baseline at Week 156 in HIV RNA (log10 copies/mL)</description>
          <population>Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace &lt;400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: Baseline carry-forward for all failures/discontinued due to lack of efficacy</population>
          <units>HIV RNA (log10 copies/mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" lower_limit="-1.55" upper_limit="-1.20"/>
                    <measurement group_id="O2" value="-0.52" lower_limit="-0.71" upper_limit="-0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Open-Label Extension - Week 240: Change From Baseline in HIV RNA (log10 Copies/mL)</title>
        <description>Mean change from baseline at Week 240 in HIV RNA (log10 copies/mL)</description>
        <time_frame>Baseline and Week 240</time_frame>
        <population>Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace &lt;400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: Baseline carry-forward for all failures/discontinued due to lack of efficacy
Participants with virologic failure after Week 16 = treatment failures</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
            <description>Raltegravir 400 mg b.i.d. plus OBT includes all participants initially randomized to raltegravir. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants continued to receive raltegravir plus OBT until Week 240.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
            <description>Placebo plus OBT includes all participants initially randomized to placebo. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants received raltegravir plus OBT until Week 240.</description>
          </group>
        </group_list>
        <measure>
          <title>Open-Label Extension - Week 240: Change From Baseline in HIV RNA (log10 Copies/mL)</title>
          <description>Mean change from baseline at Week 240 in HIV RNA (log10 copies/mL)</description>
          <population>Observed mean change from baseline in log10 plasma HIV RNA calculated using conventional imputation (replace &lt;400 copies by 400 copies if signal detected; 200 copies if not detected); Missing values: Baseline carry-forward for all failures/discontinued due to lack of efficacy
Participants with virologic failure after Week 16 = treatment failures</population>
          <units>HIV RNA (log10 copies/mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" lower_limit="-1.49" upper_limit="-1.13"/>
                    <measurement group_id="O2" value="-0.41" lower_limit="-0.59" upper_limit="-0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 16</title>
        <description>Mean change from baseline at Week 16 in CD4 cell count (cells/mm^3)</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 16</title>
          <description>Mean change from baseline at Week 16 in CD4 cell count (cells/mm^3)</description>
          <population>Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy.</population>
          <units>CD4 Cell Count (cells/mm^3)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.8" lower_limit="72.7" upper_limit="99.0"/>
                    <measurement group_id="O2" value="39.9" lower_limit="26.2" upper_limit="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 48</title>
        <description>Mean change from baseline at Week 48 in CD4 cell count (cells/mm^3)</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy.
Participants with virologic failure after Week 16 are treatment failures for virologic efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 48</title>
          <description>Mean change from baseline at Week 48 in CD4 cell count (cells/mm^3)</description>
          <population>Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy.
Participants with virologic failure after Week 16 are treatment failures for virologic efficacy analyses.</population>
          <units>CD4 Cell Count (cells/mm^3)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="84.1" upper_limit="112.7"/>
                    <measurement group_id="O2" value="39.8" lower_limit="23.5" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Double-Blind Extension - Week 156: Change From Baseline in CD4 Cell Count(Cells/mm^3)</title>
        <description>Mean change from baseline at Week 156 in CD4 cell count (cells/mm^3)</description>
        <time_frame>Baseline and Week 156</time_frame>
        <population>Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy.
Participants with virologic failure after Week 16 are treatment failures for virologic efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
          </group>
        </group_list>
        <measure>
          <title>Double-Blind Extension - Week 156: Change From Baseline in CD4 Cell Count(Cells/mm^3)</title>
          <description>Mean change from baseline at Week 156 in CD4 cell count (cells/mm^3)</description>
          <population>Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy.
Participants with virologic failure after Week 16 are treatment failures for virologic efficacy analyses.</population>
          <units>CD4 Cell Count (cells/mm^3)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.2" lower_limit="130.7" upper_limit="183.6"/>
                    <measurement group_id="O2" value="54.2" lower_limit="30.0" upper_limit="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Open-Label Extension - Week 240: Change From Baseline in CD4 Cell Count (Cells/mm^3)</title>
        <description>Mean change from baseline at Week 240 in CD4 cell count (cells/mm^3)</description>
        <time_frame>Baseline and Week 240</time_frame>
        <population>Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy.
Participants with virologic failure after Week 16 are treatment failures for virologic efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 400 mg b.i.d. + OBT</title>
            <description>Raltegravir 400 mg b.i.d. plus OBT includes all participants initially randomized to raltegravir. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants continued to receive raltegravir plus OBT until Week 240.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + OBT</title>
            <description>Placebo plus OBT includes all participants initially randomized to placebo. Those who did not experience virologic failure by Week 156 may have continued into the open-label phase. During the open-label phase, these participants received raltegravir plus OBT until Week 240.</description>
          </group>
        </group_list>
        <measure>
          <title>Open-Label Extension - Week 240: Change From Baseline in CD4 Cell Count (Cells/mm^3)</title>
          <description>Mean change from baseline at Week 240 in CD4 cell count (cells/mm^3)</description>
          <population>Observed failure approach assuming baseline-carry-forward for all failures, exclude other missing values. Baseline CD4 cell count (cells/mm^3) was carried forward for participants who discontinued assigned therapy due to lack of efficacy.
Participants with virologic failure after Week 16 are treatment failures for virologic efficacy analyses.</population>
          <units>CD4 Cell Count (Cells/mm^3)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.1" lower_limit="141.7" upper_limit="202.5"/>
                    <measurement group_id="O2" value="54.1" lower_limit="27.1" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>240 Weeks</time_frame>
      <desc>Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 83 of 119 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir 400 mg b.i.d. Plus OBT</title>
          <description>Includes all participants initially randomized to raltegravir, including those without virologic failure who
continued into the open-label phase at Week 156 and those who entered the OLPVF phase due to virologic failure. During either open-label phase up to Week 240, these participants continued to receive raltegravir 400 mg b.i.d. plus OBT.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Plus OBT</title>
          <description>Includes all participants initially randomized to placebo, including those without virologic failure who continued into the open-label phase at Week 156 and those who entered the OLPVF phase due to virologic failure. During either open-label phase up to Week 240, these participants continued to receive raltegravir 400 mg b.i.d. plus OBT.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness cortical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Immune reconstitution syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS dementia complex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abscess bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Acinetobacter bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Acute HIV infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cryptococcosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cryptosporidiosis infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>HIV wasting syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Salmonella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Anal cancer stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Head and neck cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma AIDS related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lip neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Malignant anorectal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="230"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="230"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="230"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="230"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="230"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="108" subjects_affected="75" subjects_at_risk="230"/>
                <counts group_id="E2" events="41" subjects_affected="35" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="230"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="57" subjects_affected="41" subjects_at_risk="230"/>
                <counts group_id="E2" events="40" subjects_affected="30" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="41" subjects_affected="25" subjects_at_risk="230"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="57" subjects_affected="45" subjects_at_risk="230"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="230"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="230"/>
                <counts group_id="E2" events="35" subjects_affected="24" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="44" subjects_affected="34" subjects_at_risk="230"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="230"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="230"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="50" subjects_affected="29" subjects_at_risk="230"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="230"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="50" subjects_affected="35" subjects_at_risk="230"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="114" subjects_affected="76" subjects_at_risk="230"/>
                <counts group_id="E2" events="47" subjects_affected="29" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="18" subjects_at_risk="230"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="230"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="230"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="37" subjects_affected="18" subjects_at_risk="230"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="22" subjects_at_risk="230"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="230"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="24" subjects_at_risk="230"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="230"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="230"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="230"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="35" subjects_affected="27" subjects_at_risk="230"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="230"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="230"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="62" subjects_affected="39" subjects_at_risk="230"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="230"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="230"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="230"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="230"/>
                <counts group_id="E2" events="29" subjects_affected="21" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="230"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="36" subjects_affected="30" subjects_at_risk="230"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="230"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial, but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 83 of 119 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

